DFMO Shows Potential in the Prevention of Cervical Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 6
Volume 5
Issue 6

NEW ORLEANS--In a phase I trial from M.D. Anderson Cancer Center, the chemopreventive agent difluorometh-ylornithine (DFMO) produced significant regression of cervical intraepithelial neoplasia (CIN) grade 3, Michele Follen Mitchell, MD, reported at the Society of Gynecologic Oncologists meeting.

NEW ORLEANS--In a phase I trial from M.D. Anderson Cancer Center,the chemopreventive agent difluorometh-ylornithine (DFMO) producedsignificant regression of cervical intraepithelial neoplasia (CIN)grade 3, Michele Follen Mitchell, MD, reported at the Societyof Gynecologic Oncologists meeting.

DFMO is a suicide inhibitor of ornithine decarboxylase, a stepalong the polyamine synthesis chain to carcinogenesis, and isbelieved to be a strong antiprolif-erative agent. It has beenused in the treatment of colon cancer.

The study included 30 patients treated for 30 days with one offour doses of DFMO in elixir form: 1.0, 0.5, 0.25, and 0.06 g/m²/day.

After treatment, the patients underwent biopsies for polyaminesynthesis markers followed by loop electrosurgical excision ofthe cervix for complete his-topathologic study. Blood was drawnfor red cell polyamine synthesis markers and serum ornithine andarginine levels. One patient was excluded from analysis, leaving29 for evaluation.

Despite the short duration of treatment, five patients experienceda complete response, and 10 patients had a 50% response, showingregression of the lesion from CIN 3 to CIN 1 or 2. The DNA indexconfirmed the significance of the changes from pretreatment topost-treatment biopsies, Dr. Mitchell said.

While the classic polyamine markers were modulated, these changeswere not significant, probably because of the small sample size,Dr. Mitchell said.

Tissue polyamine modulation, as measured by the spermidine/spermineratio, on the other hand, was significantly changed at a DFMOdose of 1.0 g. Serum polyamine modulation, as measured by plasmaarginine, was also significantly modulated at the 1.0 g dose.This suggests that parts of the polysynthesis chain were blocked,possibly impeding car-cinogenesis, she said.

The provides optimism for the potential use of DFMO in the preventionof cervical cancer and will be further examined in a phase IIstudy, she said.

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Related Content